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Phytosterols protect against diet-induced
hypertriglyceridemia in Syrian golden hamsters
Todd C Rideout1*, Vanu Ramprasath2, John D Griffin1, Richard W Browne3, Scott V Harding4 and Peter JH Jones2
Abstract
Background: In addition to lowering LDL-C, emerging data suggests that phytosterols (PS) may reduce blood
triglycerides (TG), however, the underlying mechanisms are not known.
Methods: We examined the TG-lowering mechanisms of dietary PS in Syrian golden hamsters randomly assigned
to a high fat (HF) diet or the HF diet supplemented with PS (2%) for 6 weeks (n = 12/group). An additional subset
of animals (n = 12) was provided the HF diet supplemented with ezetimibe (EZ, 0.002%) as a positive control as it is
a cholesterol-lowering agent with known TG-lowering properties.
Results: In confirmation of diet formulation and compound delivery, both the PS and EZ treatments lowered
(p < 0.05) intestinal cholesterol absorption (24 and 31%, respectively), blood non-HDL cholesterol (61 and 66%,
respectively), and hepatic cholesterol (45 and 55%, respectively) compared with the HF-fed animals. Blood TG
concentrations were lower (p < 0.05) in the PS (49%) and EZ (68%)-treated animals compared with the HF group.
The TG-lowering response in the PS-supplemented group was associated with reduced (p < 0.05) intestinal SREBP1c
mRNA (0.45 fold of HF), hepatic PPARα mRNA (0.73 fold of HF), hepatic FAS protein abundance (0.68 fold of HD),
and de novo lipogenesis (44%) compared with the HF group. Similarly, lipogenesis was lower in the EZ-treated
animals, albeit through a reduction in the hepatic protein abundance of ACC (0.47 fold of HF).
Conclusions: Study results suggest that dietary PS are protective against diet-induced hypertriglyceridemia, likely
through multiple mechanisms that involve modulation of intestinal fatty acid metabolism and a reduction in
hepatic lipogenesis.
Keywords: Phytosterols, Ezetimibe, Triglycerides, Lipogenesis
Background
Although LDL-C levels have decreased among US adults
in recent years largely due to the widespread and effective
use of lipid lowering medication, hypertriglyceridemia is
increasingly prevalent with 33.1% of Americans having
borderline high triglyceride (TG) levels [1]. This mean in-
crease in TG concentrations amongst men and women
over the past 20 years has coincided with the alarming
obesity trend and is further associated with increased risk
of acute pancreatitis and cardiovascular disease (CVD) [2].
Data from the National Health and Nutrition Examination
Survey (NHANES) suggests that > 80% of overweight
(BMI 25–30 kg/m2) and obese (BMI ≥30 kg/m2) subjects
have TG concentrations ≥1.69 mmol/L [3].
Moderate hypertriglyceridemia (1.69-2.24 mmol/L) is
treated with body weight reduction through lifestyle
modifications of diet and physical activity while severe
cases (>5.6 mmol/L) require first-line drug therapy with
a range of pharmaceuticals including statins, fibrates,
niacin, and prescription n-3 fatty acids [4]. Marine-
derived n-3 fatty acids are considered the most effective
nutraceutical TG-lowering option (~30%), however, phy-
tosterols (PS) have recently been explored for their poten-
tial TG-lowering effects beyond their established LDL-C
lowering efficacy. Although the majority of clinical PS
intervention studies have failed to observe significant TG
lowering responses, two studies specifically designed
to examine the TG-lowering potential of PS reported
reductions in the range of 11-27%, depending on baseline
TG concentration [5,6]. The precise mechanism (s) re-
sponsible for the TG-lowering effects of PS are not known,
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however, we recently observed an increase in fecal
saturated fatty acid excretion in C57Bl6 mice fed a PS-
enriched diet, suggesting a possible interference with
intestinal fat absorption [7]. Furthermore, although
previous work suggests that PS may be effective in re-
ducing TG in subjects with established, overt hypertri-
glyceridemia, it is unknown if PS provides protection
against diet-induced increases in TG following high fat
feeding. Considering the effectiveness of PS in redu-
cing LDL-C by interfering with intestinal cholesterol
absorption, knowledge of the TG-lowering potential of
PS and the underlying mechanisms involved will be
critical in ascertaining the utility of PS as a potential
therapy against mixed dyslipidemia. Therefore, the object-
ive of this study was to examine the effectiveness of PS in
protecting against diet-induced hypertriglyceridemia in
Syrian golden hamsters fed a high fat TG-raising diet.
We utilized EZ as a comparative control as it is another
well-characterized cholesterol-absorptive inhibitor that
is recognized to reduce circulating TG concentrations
in humans and a previous study using the Syrian golden
hamster [8].
Results
Establishment of diet-induced dyslipidemic model
Table 1 demonstrates whole-body growth and blood lipid
endpoints in response to the consumption of the HF
versus the LF diet. HF feeding for six weeks increased
(p < 0.05) final body weight and blood lipid concentra-
tions including total-C, HDL-C, non-HDL-C, and TG.
Although plasma aspartate transaminase (AST) did not
differ (p > 0.05) between the two groups, plasma alanine
aminotransferase (ALT) was higher (p < 0.05) in the
HF versus the LF group, suggesting a potential hepatic
inflammatory response to HF feeding.
Blood lipid and sterols
As expected, total, non-HDL-C, and HDL-C were lower
in the PS (34, 61, and 12.5%) and EZ (39, 66, and 21.6%)
groups versus the HF-fed animals with no difference be-
tween the PS and EZ groups (Figure 1A, B, C). Further-
more, blood TG concentrations were lowered (p < 0.05)
to a similar extent with PS (49%) and EZ (68%) therapy
compared with the HF group (Figure 1D). Dietary PS
and EZ supplementation resulted in similar reductions
(p < 0.05) in plasma concentrations of CE-16:0, CE-18:1,
and CE-18:2 versus the HF group (Figure 1E). PS feeding
led to an expected increase (p < 0.05) in RBC campesterol
and sitosterol concentrations compared with the HF and
EZ groups (Figure 2) but also reduced (p < 0.05) RBC des-
mosterol concentrations compared with the other groups.
EZ supplementation increased (p < 0.05) RBC desmosterol
and lathosterol concentrations compared with the HF and
PS groups (Figure 2).
Hepatic cholesterol and fatty acids
Hepatic cholesterol was lowered similarly in the PS (45%)
and the EZ (55%) groups compared with the HF-fed ani-
mals (Figure 3). No difference in total hepatic fatty acids
was observed, however, PS and EZ treatment produced
in a similar shift in hepatic fatty acid composition by in-
creasing 16:0 (~50%) and reducing 16:1 (~40%) and 18:1
(~24%) compared with the HF-fed animals (Figure 3).
Stable isotope analyses
Cholesterol absorption was lowered (p < 0.05) to a similar
extent in the PS (27%) and EZ (37%) groups, compared
with the HF group (Figure 4). Compared with the HF
group, hepatic de novo lipogenesis was lowered (p < 0.05)
by feeding PS (44%) and EZ (70%) with no difference
between the PS and EZ groups.
mRNA and protein expression
No changes in intestinal NPC1L1, FABP1, or CD36 were
observed in response to PS or EZ versus the HF group
(data not shown). Compared with the HF group, SREBP1c
mRNA expression was lowered (p < 0.05) in response to
PS (0.45 fold of HF) and EZ supplementation (0.69 fold of
HF, Figure 5A). However, EZ treatment lowered NPC1L1
protein abundance (0.69 fold of HF) compared with the
HF and PS groups (Figure 5B).
Compared with the HF group, hepatic FAS protein
abundance was lowered (0.68 fold of HF, p < 0.05) with
PS consumption but was not affected by EZ therapy
(Figure 6A). EZ lowered hepatic ACC protein abundance
Table 1 Establishment of high fat feeding model on body
weight and blood lipid parameters in Syrian golden
hamsters2
Diets
Item LF1 HF1
Whole body parameters
Initial body weight (g) 124.13 ± 1.81 126.21 ± 1.81
Final body weight (g) 139.58 ± 3.27 151.18 ± 3.42*
Body weight change (%) 15.18 ± 2.64 25.75 ± 2.75*
Blood biochemistry
Total cholesterol (mmol/L) 4.65 ± 0.31 6.45 ± 0.31*
Non-HDL cholesterol (mmol/L) 2.19 ± 0.21 2.87 ± 0.21*
HDL-cholesterol 2.45 ± 0.21 3.57 ± 0.21*
Triglycerides (mmol/L) 2.48 ± 0.46 5.26 ± 0.46*
Glucose (mmol/L) 10.76 ± 0.66 12.16 ± 0.87*
AST (U/L) 90.18 ± 11.92 86.20 ± 8.90
ALT (U/L) 62.0 ± 8.24 83.60 ± 8.32*
1LF, low fat control diet; HF, High fat diet.
2mean ± SEM, n = 12.
*Significantly different from LF (p < 0.05).
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Figure 1 Blood lipid response to phytosterol and ezetimibe therapy in Syrian golden hamsters. (A) total cholesterol (mmol/L); (B) non-HDL
cholesterol (mmol/L); (C) HDL-cholesterol (mmol/L); (D) triglyceride (mmol/L); (E) Plasma cholesterol esters (nmol/L) including cholesteryl palmitate
(CE-16:0), cholesteryl oleate (CE-18:1), cholesteryl-linoleate (CE-18:2) and cholesteryl arachidonate (CE 20:4). abGroups not sharing a superscript are
significantly different (p < 0.05). The dashed line in A, B, C and D represent the mean lipid response following consumption of the LF diet.
Figure 2 Red blood cell phytosterols (nmol/g) in response to phytosterol and ezetimibe therapy in Syrian golden hamsters. abGroups
not sharing a superscript are significantly different (p < 0.05).
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(0.47 fold of HF, p < 0.05) compared with the HF group,
but was not affected by PS supplementation (Figure 6B).
Compared with the HF group, PPARα protein abundance
was lowered (0.73 fold of HF, p < 0.05) in the PS group but
not affected by EZ supplementation (Figure 6C).
Discussion
Findings from this study suggest that dietary PS, in
addition to their established cholesterol-lowering proper-
ties, may also protect against diet-induced hypertriglyc-
eridemia. This TG-lowering response appears to be due to
modulation of fat metabolism in the intestine and the liver
as evidenced by a reduction in intestinal SREBP1c and
PPARα mRNA expression and a decrease in hepatic FAS
protein abundance and de novo lipogenesis. These results
would seem to confirm the limited animal [9,10] and hu-
man data [5,11] that suggests a TG-lowering response to
PS supplementation and suggest that PS may be effective
in protecting against diet-induced mixed dyslipidemia.
In this diet-induced hypertriglyceridemic hamster model,
blood and tissue lipid responses to PS supplementation
were comparable to those observed with EZ, a suitable
positive control as it has a similar cholesterol-lowering
effect to PS but also possesses a more well-characterized
effect on TG metabolism including reductions in blood
TG [12-15] and amelioration of hepatic TG accumulation
[16] and steatosis [17,18]. As a confirmation of both the
diet composition and experimental protocol, both PS and
EZ-treated animals demonstrated an expected inhibition
of intestinal cholesterol absorption and a reduction in
blood total and non-HDL-C cholesterol below that of the
LF-fed animals. Although it is not completely understood
how a cholesterol-absorptive inhibitor could modulate TG
metabolism, a few recent reports have examined the issue
specifically with EZ.
Naples et al. (2012) suggested that EZ may lower post-
prandial TG by modulating intestinal fatty acid absorp-
tion and chylomicron assembly by reducing apoB48
production and modulating the expression of intestinal
lipid synthesis and transport genes in fructose and fat-fed
hamsters [19]. Similarly, we observed a reduction in intes-
tinal SREBP1c mRNA in both the EZ and PS groups, thus
confirming the previous report by Naples et al. (2012) and
further suggesting that PS may reduce blood TG through
a similar intestinal SREBP1c-related mechanism. It is
not known why we did not observe a corresponding re-
duction in the cytoplasmic or nuclear protein abundance
of SREBP1c in the PS and EZ groups. We previously re-
ported a reduction in intestinal PPARα mRNA expression
and increased fecal FA loss in C57BL/6 J mice fed a PS
Figure 3 Hepatic cholesterol (A, mg/g) and fatty acid (B, % composition) in response to phytosterol and ezetimibe therapy in Syrian
golden hamsters. abGroups not sharing a superscript are significantly different (p < 0.05).
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supplemented diet [7]. Taken together, it appears that at
least part of the TG-lowering effects of PS is associated
with the modulation of multiple intestinal FA regulatory
targets.
With the knowledge that excessive hepatic cholesterol is
lipogenic through the activation of the liver X-receptor
(LXR) [20,21], a more direct link between the cholesterol-
lowering properties of EZ and TG-reductions has been
proposed. In a HF-fed hamster model, Ushio et al. (2013)
reported that in response to a limitation in intestinal
cholesterol absorption, EZ reduced hepatic oxysterol
LXRα ligands, thus inhibiting LXRα-induced transcrip-
tional stimulation of SREBP-1c [17]. However, after fail-
ing to observe a reduction in SREBP1c lipogenic targets
in the EZ-treated animals, the authors concluded that
EZ did not likely reduce hepatic lipogenesis through this
pathway. Contrary to this conclusion, our results suggest
that EZ reduces ACC protein abundance and inhibits hep-
atic de novo lipogenesis. Our results further suggest that
PS supplementation may modulate hepatic fat metabolism
through a similar reduction in hepatic lipogenesis, albeit
through a reduction in the protein abundance of FAS.
Further work is required to determine if this reduction in
hepatic lipogenesis in PS-supplemented animals is directly
related to the observed reduction in hepatic cholesterol
concentration and an associated inhibitory effect on the
LXRα-SREBP1c lipogenic stimulus pathway. The observed
reduction in hepatic lipogenesis in PS-supplemented ham-
sters is in direct contrast to our previous report of in-
creased lipogenesis in C57BL/6 J PS-supplemented mice
[7]. Given the similarity in the design factors between the
two studies, including diet, feeding protocol and stable
isotope analysis, this discrepancy highlights the underlying
differences in lipid metabolism amongst rodent species
and cautions against premature translation of biological
efficacy and mechanistic data regarding potential disease
treatment strategies from animal models [22].
Although hepatic fatty acid profile is a major deter-
minant of de novo lipogenesis, this does not appear to be
a contributing factor to explain the reduced fatty acid
synthesis observed in the PS and EZ treated animals.
Both fatty acid chain length and degree of unsaturation
affect lipogenic gene expression, with monounsaturated
fatty acids (MUFA) and longer-chain polyunsaturated
Figure 4 Cholesterol absorption (A) and de novo lipogenesis (B) in response to phytosterol and ezetimibe therapy in Syrian golden
hamsters. abGroups not sharing a superscript are significantly different (p < 0.05).
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fatty acids (PUFA) having a general inhibition and satu-
rated fatty acids (SFA) having a stimulatory effect in
parallel with fatty acid elongation pathways [23]. As both
PS and EZ both shifted the hepatic FA profile towards
an increase in palmitate (~50%) and a reduction in oleic
acid (~24%), it appears that modulation of hepatic fatty
acid distribution was not a determinant in the observed
reduction in lipogenesis observed in these groups. Al-
though little work has examined hepatic FA concentra-
tion in response to PS, our results are supported by a
previous report by Brufau et al. (2006) suggesting an
increase in the hepatic SFA fraction in guinea pigs
supplemented with PS [24].
Intracellular hepatic fatty acids also serve as lipid sig-
naling molecules by inducing PPARα activation. In this
way, PPARα is thought to protect against fat accumula-
tion by enhancing expression of rate-limiting enzymes in
the β-oxidation pathway. Previous work suggests that a
wide spectrum of fatty acids are capable of transactivating
PPARα and inducing DNA binding activity, particular long
chain PUFA [25]. However, as we observed no change in
hepatic total fatty acids and a reduction in 18:2 in the
PS-supplemented group, the underlying mechanisms and
physiological implication of reduced PPARα abundance is
unclear.
Although inclusion of EZ as a comparative control to
examine the TG-lowering mechanisms of PS may be
considered a study strength, direct comparison of the
lipid-lowering magnitude between the PS and EZ groups
may not be appropriate given that the dietary inclusion
levels, although similar to those typically used in previous
animal studies, exceeds normal PS intakes (2 g/d) and EZ
prescribed doses (~10 mg/d) in humans. Although the
cholesterol-lowering response to PS (~10%) and EZ
(~20%) are fairly consistent, the magnitude of TG lower-
ing is considerably more variable for both PS (6-15%) and
EZ (10-20%) and likely dependent on baseline TG concen-
trations [11,26-28].
Conclusions
Here, we demonstrate that PS supplementation offers
protection against diet-induced hypertriglyceridemia in
Figure 5 Intestinal mRNA and protein expression following phytosterol and ezetimibe therapy in Syrian golden hamsters. (A) SREBP1c
mRNA and (B) NPC1L1 protein abundance. All genes normalized to the HF group and expressed relative to β-actin. abGroups not sharing a
superscript are significantly different (p < 0.05).
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Syrian golden hamsters fed a high fat diet. Our data sug-
gest that several mechanisms, namely reductions in dietary
fat absorption, intestinal SREBP1c mRNA expression, hep-
atic PPARα abundance, and de novo lipogenesis may be
contributing to the reduction in circulating TG. Clarifica-
tion of the mechanisms underlying these TG reductions
may broaden the clinical utility of PS supplementation
beyond LDL-C lowering to a potential therapy for mixed
dyslipidemias.
Methods
Animals and diet
The animals used in this experiment were cared for in ac-
cordance with the guidelines established by the Canadian
Council of Animal Care [29]. All procedures were
reviewed and approved by the Animal Care Committee
at the University of Manitoba (protocol number F06-
013/1/2). Forty-eight male Syrian golden hamsters were
acquired from Charles Rivers and brought to the Animal
Model Research Facility at the Richardson Centre for
Functional Foods and Nutraceuticals at the University of
Manitoba. Hamsters were housed individually in cages
with shavings in a temperature-controlled room (20°C)
with a 12 h light/dark cycle and had free access to water.
At the initiation of the experiment, hamsters were
randomly assigned to 1 of 3 treatment diets (n = 12) for
6 weeks according to Table 2: (1) High fat diet (HF, AIN
76A Western Diet); (2) HF diet supplemented with 2%
PS (Reducol, Forbes Meditech); (3) HF diet supple-
mented with 0.002% EZ [8] (Merck/Schering-Plough
Figure 6 Hepatic protein abundance following phytosterol and ezetimibe therapy in Syrian golden hamsters. (A) FAS protein
abundance; (B) ACC protein abundance; (C) PPARα protein abundance. All proteins normalized to the HF group and expressed relative to β-actin.
abGroups not sharing a superscript are significantly different (p < 0.05).
Rideout et al. Lipids in Health and Disease 2014, 13:5 Page 7 of 11
http://www.lipidworld.com/content/13/1/5
Pharmaceuticals). An additional group of animals was
maintained on a low fat diet (LF, AIN76) to establish
the effects of the HF feeding on obesity, and hepatic and
plasma lipid response.
Sample collection and processing
Following the 6-week feeding period, hamsters were
anesthetized with isoflurane for blood and tissue collection
then killed by exsanguination while in the surgical plane of
anesthesia. Fasting (8 hrs) blood (serum and EDTA plasma)
was collected by cardiac puncture and processed as previ-
ously described [7]. The liver and proximal small intestine
were quickly excised, rinsed/flushed in chilled saline
(pH 7.4, 154 mM containing 0.1 mM phenylmethylsulfonyl
fluoride) and flash frozen in liquid nitrogen. All tissues
were stored at −80°C until further processing and analyses.
Blood lipid and sterol analyses
Plasma total cholesterol (TC), high-density lipoprotein
cholesterol (HDL-C), non-HDL cholesterol (non-HDL-C),
and TG were determined by automated enzymatic
methods on a Vitros 350 chemistry analyzer (Ortho-
Clinical Diagnostics, Markham, Ontario, Canada). Non-
HDL-C was calculated by difference.
Serum free cholesterol and cholesteryl esters were
measured by high performance liquid chromatography
(HPLC) according to our modification of Vercaemst
et al. [30]. Briefly, one volume of serum was diluted with
five volumes of isopropanol containing cholesteryl hepta-
decanoate as the internal standard. Samples were vortexed
for 30 minutes, centrifuged, and injected (50 uL) onto a
25 cm × 4.6 mm reverse phase column using an isocratic
mobile phase of acetonitrile/isopropanol (60:40 v/v) at a
flow rate of 2.0 mL/min and 45°C. Unesterified cholesterol
and cholesteryl esters [palmitate (CE-16:0), oleate (CE-
18:1), linoleate (CE-18:2), and arachidonate (CE-20:4)]
were detected by their UV absorbance at 208 nm and
quantified in comparison to pure standards after cor-
recting for internal standard recovery.
Red blood cell PS concentrations were determined by
gas–liquid chromatography according to previously estab-
lished procedures [31] using a gas chromatography (6890
GC, Agilent Technologies, Palo Alto, California) equipped
with flame ionization detector and auto-injector system.
A 30-m SAC-5 column (Sigma-Aldrich Canada Ltd.,
Oakville, Ont.) was used. Briefly, 5-α cholestane as an
internal standard was added to each of the samples
followed by addition of methanolic potassium hydroxide
and saponification. Sterols were extracted from the mixture
with petroleum ether. Extracted samples were deriva-
tized with TMS reagent (pyridine-hexamethyldisilazan-
trimethylchlorosilane (9:3:1, v/v)) and samples were
injected into the GC. The injector and detector were set
at 300 and 310 degrees C, respectively. The flow rate of
the carrier gas, helium was 1.2 ml/min with the inlet
splitter set at 100:1. Individual PS were identified using
authentic standards (Sigma-Aldrich Canada Ltd., Oakville,
Ont). Internal standards were used to calculate detector
response factors. Campesterol and β-sitosterol concen-
trations were determined by identifying the peak sizes
and expressing them relative to 5-α cholestane internal
standard.
Hepatic sterol and fatty acid analyses
Hepatic cholesterol was extracted and analyzed according
to our previously published procedures [7,32]. Approxi-
mately 500 mg of pulverized liver was spiked with α-
cholestane as internal standard and saponified in freshly
prepared KOH–methanol at 100°C for 1 h. The non-
saponifiable sterol fraction was extracted with petroleum
diethyl ether and dried under N2 gas. For analysis of hep-
atic fatty acids, approximately 0 · 5 g of pulverized liver
was spiked with heptadecanoic acid (C17:0) as internal
standard. Total lipids were isolated from liver tissue with a
Table 2 Formulation of experimental diets (%) for Syrian
golden hamsters
Diets1
Ingredient LF HF PS EZ
Sucrose 12 34.1 34.1 34.1
Milk fat 3.7 19.96 19.96 19.96
Casein 19.5 19.47 19.47 19.47
Maltodextrin 10 9.99 9.99 9.99
Corn starch 43.2 4.99 4.99 4.99
Phytosterol mix2 - - 2 -
Ezetimibe3 - - - 0.002
Powdered cellulose 5 4.99 2.99 4.99
AIN76-A mineral mix 3.5 3.49 3.49 3.49
AIN76-A vitamin mix 1 0.99 0.99 0.99
Corn oil 1.2 0.99 0.99 0.99
Calcium carbonate 0.4 0.39 0.39 0.39
DL-methionine 0.3 0.29 0.29 0.29
Choline bitartrate 0.2 0.19 0.19 0.19
Cholesterol - 0.15 0.15 0.15
Ethoxyquin 0.001 0.005 0.005 0.005
Total 100 100 100 100
Energy (%)
Fat 11.8 40.0 40.0 40.0
Carbohydrate 69.1 44.2 44.2 44.2
Protein 19 15.8 15.8 15.8
1LFD, low fat/low cholesterol control; HF, high fat diet; PS, plant sterol;
EZ, ezetimibe.
2Reducol, Forbes Meditech (Campestanol 7% w/w; Stigmasterol <1% w/w;
sitosterol 71% w/w; sitostanol 15% w/w).
3Merck/Schering-Plough Pharmaceuticals.
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modified Dole mixture (3 hepatane:12 propanol:3 DDH2O,
vol:vol) followed by extraction with heptane: DDH2O (3:1
vol:vol) [33]. Fatty acid extracts were methylated with
methanolic boron trifluoride (Sigma Aldrich, St. Louis,
MO).
Sterol and fatty acid fractions were analyzed using a
Shimadzu GC-17A gas chromatograph fitted with a
flame ionization detector. A SAC-5 capillary column
(30 m × 0 · 25 mm × 0 · 25 mm, Supelco, Bellefonte, CA,
USA) was used for cholesterol analyses. Fatty acid methyl
esters were separated using a Supelcowax 10 column
(30 m × 0 · 25 mm with 0 · 25 m film thickness; Supelco,
Bellefonte, PA, USA). Relative hepatic fatty acid content
was calculated by using individual FA peak area relative to
the total area and expressed as the percentage of total fatty
acids.
Intestinal RNA preparation and real-time RT-PCR
Total RNA was isolated from whole intestinal tissue
using TRIzol reagent (Invitrogen Canada Inc., Burlington,
ON). RNA concentration and integrity was determined
with spectrophotometry (260 nm) and agarose gel elec-
trophoresis, respectively. RNA preparation and real-time
RT-PCR was conducted using a one-step QuantiTect
SYBR Green RT-PCR kit (Qiagen Inc., Mississauga, ON,
Canada) on a Biorad MyiQ real time PCR system accord-
ing to previously established protocols [34]. Sequences of
sense and antisense primers for target and housekeeping
genes were based on previously published reports for
NPC1L1 [35], CD36, FABP2 [36], SREBP1c, [37], and
β-actin [38].
Immunoblot analysis of intestinal and hepatic regulatory
proteins
Immunoblots were prepared as previously described [34].
Nuclear and cytoplasmic extracts for immunoblot ana-
lyses of peroxisome proliferator-activated receptor alpha
(PPARα, SC-9000, Santa Cruz Biotechnology), SREBP1c
(Novus Biologicals, NB600-582), fatty acid synthase (FAS,
C2OG5, Cell Signaling), and acetyl-CoA carboxylase
(ACC, C83B10, Cell Signaling), were separated using the
CelLytic™ NuCLEAR™ extraction kit (Sigma, Saint Louis,
Missouri, USA). Intestinal apical membrane extracts
were extracted according to a previously established
protocol probed for NPC1L1 (Santa Cruz, sc-67237)
[39]. Target proteins were normalized to β-actin and
quantified using Image J (National Institutes of Health,
Bethesda, Maryland).
Stable isotope analyses
Hamsters were given an intraperitoneal injection of deu-
terium (100 μl) 2-hours prior to euthanization. Lipogenesis
rates (%/day) were quantified using the uptake rate of
deuterium from body water into newly synthesized
hepatic-palmitate extracts over 2 h at the end of the
feeding experiment [40,41]. Deuterium enrichment of
hepatic-palmitate was quantified using an on-line gas
chromatography/combustion/isotope ratio mass spec-
trometry approach (Agilent 6890 N chromatograph
interfaced with a Thermo Delta V Plus isotope ratio
mass spectrometer (Bremen, Germany). Isotope abun-
dance, expressed in delta (δ) per mil (‰), was calculated
in hepatic-palmitate and plasma water (precursor pool)
using H2 as a reference gas and further corrected against
the international reference, Standard Mean Ocean Water
(SMOW). De novo lipogenesis rates were calculated with
the following equation:
De novo lipogenesis %=dayð Þ
¼ ΔTGFA ‰ð Þ=Δplasma ‰ð Þ  0:477  100
Where ΔTGFA is the change in deuterium enrichment
in hepatic-palmitate; Δplasma is the change in the deu-
terium enrichment of the precursor plasma water; and
0.477 is derived from 0.87 g-atom 3H per g-atom carbon
incorporated into adipose tissue fatty acids and a correc-
tion factor to account for the glycerol moiety as previously
described [42]. Lipogenesis rates are expressed relative to
the HF group.
Forty-eight hours prior to euthanization, hamsters were
given an oral gavage of safflower oil containing 5 mg of
[3,4]-13C cholesterol (99% enriched; CDN Isotopes). As
an indicator of cholesterol absorption, GC-combustion-
isotope ratio MS (Delta V Plus, Thermo Scientific) was
used to determine the 13C enrichment (13C/12C ratio) of
free cholesterol in RBC compared with the non-enriched
hamster RBC 13C-cholesterol enrichment over 48 h [43].
Statistical analyses
Data were analyzed with a general linear model ANOVA
using experimental block as a fixed factor [44]. To estab-
lish the effect of HF-feeding, responses between the LF
versus the HF groups were compared using a paired t-test.
Multiple comparisons between treatment groups were
analyzed with Tukey’s post-hoc test. Data were analyzed
with SPSS 16 for Mac (SPSS Inc, Chicago IL). Data are
presented as mean ± SEM. All results are the means
from 12 animals unless otherwise stated. Differences
were considered significant at p ≤ 0.05.
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